港股異動 | 石四藥集團(2005.HK)漲10% 公司兩產品中選國家集採
格隆匯6月25日丨石四藥集團(2005.HK)股價高開高走,現報5.39港元,漲幅10.2%,最新總市值163.1億港元。公司24日公吿稱,集團新產品安瓿包裝的鹽酸羅哌卡因注射液及氟康唑氯化鈉注射液於6月23日的中國全國藥品集中採購招標中分別以第三及第二順位中標。董事局預期是次中標將有利相關產品迅速開發市場,形成規模銷售,提高市場佔有率,對集團未來銷售帶來正面的影響。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.